BMRN acquires FOLD for $14.50/sh cash—a 33% premium to yesterday’s close: https://www.prnewswire.com/news-releases/biomarin-to-acquire-amicus-therapeutics-for-4-8-billion-expanding-position-as-a-leader-in-rare-diseases-accelerating-revenue-growth-and-strengthening-financial-outlook-302646880.html The nominal deal value is $4.8B.